Michael Barbella, Managing Editor01.28.23
Diabetes, dementia, and strokes were the topics of choice this week on MPO's website.
Cybervisitors gravitated toward studies from Johnson & Johnson MedTech subsidiary Biosense Webster Inc. and Medtronic on catheter ablation treatment and post-stroke workflow protocols (respectively). Diabetes-related news from Abbott and Tandem Diabetes also proved popular.
Driving the most website traffic was Biosense Webster's revelation that AFib patients treated with catheter ablation had a 41% lower risk of dementia compared with those treated with anti-arrhythmic drugs (1.9% vs 3.3%; hazard ratio [HR] 0.59, 95% confidence interval [CI] 0.52-0.67). Published in the American Heart Journal, the study evaluated non-specific catheter claims information and found that CA significantly lowered dementia risk compared to AAD treatment only.
Medtronic also amassed page views by sharing encouraging first results from the DiVERT Stroke clinical study, which showed that post-stroke workflow protocols and cardiac monitoring vary significantly across community hospitals and academic centers. The first-of-its kind, multi-center study evaluated more than 7,600 cryptogenic, large-artery and small-vessel stroke patients across 12 U.S. hospitals and found more than 75% of cryptogenic stroke patients at large academic centers received some form of cardiac monitoring (i.e. external cardiac monitor, implantable loop recorders), versus 5% of cryptogenic stroke patients at community hospitals. It also found that community hospitals were half as likely to consult cardiology than academic centers (16% vs. 34%; p<0.001).
Abbott Labs satisfied website loyalists' craving for diabetes news with word of FDA approval of its Proclaim XR spinal cord stimulation (SCS) system for painful diabetic peripheral neuropathy treatment. The Proclaim XR SCS provides an alternative to traditional treatment approaches like oral medication. Those receiving therapy from the system also have access to Abbott’s NeuroSphere virtual clinic, a connected care app for people to communicate with a physician and receive remote treatment adjustments.
Tandem Diabetes followed suit by completing the previously announced deal for AMF Medical, Swiss developer of the Sigi patch pump.
Cybervisitors gravitated toward studies from Johnson & Johnson MedTech subsidiary Biosense Webster Inc. and Medtronic on catheter ablation treatment and post-stroke workflow protocols (respectively). Diabetes-related news from Abbott and Tandem Diabetes also proved popular.
Driving the most website traffic was Biosense Webster's revelation that AFib patients treated with catheter ablation had a 41% lower risk of dementia compared with those treated with anti-arrhythmic drugs (1.9% vs 3.3%; hazard ratio [HR] 0.59, 95% confidence interval [CI] 0.52-0.67). Published in the American Heart Journal, the study evaluated non-specific catheter claims information and found that CA significantly lowered dementia risk compared to AAD treatment only.
Medtronic also amassed page views by sharing encouraging first results from the DiVERT Stroke clinical study, which showed that post-stroke workflow protocols and cardiac monitoring vary significantly across community hospitals and academic centers. The first-of-its kind, multi-center study evaluated more than 7,600 cryptogenic, large-artery and small-vessel stroke patients across 12 U.S. hospitals and found more than 75% of cryptogenic stroke patients at large academic centers received some form of cardiac monitoring (i.e. external cardiac monitor, implantable loop recorders), versus 5% of cryptogenic stroke patients at community hospitals. It also found that community hospitals were half as likely to consult cardiology than academic centers (16% vs. 34%; p<0.001).
Abbott Labs satisfied website loyalists' craving for diabetes news with word of FDA approval of its Proclaim XR spinal cord stimulation (SCS) system for painful diabetic peripheral neuropathy treatment. The Proclaim XR SCS provides an alternative to traditional treatment approaches like oral medication. Those receiving therapy from the system also have access to Abbott’s NeuroSphere virtual clinic, a connected care app for people to communicate with a physician and receive remote treatment adjustments.
Tandem Diabetes followed suit by completing the previously announced deal for AMF Medical, Swiss developer of the Sigi patch pump.